CollPlant Biotechnologies (CLGN) Cash from Operations (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Cash from Operations came in at 2935000.0 in Q4 2025, up 15.27% YoY from 2546165.79 in Q4 2024, and down 2.02% on a QoQ basis from 2877000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Cash from Operations (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Cash from Operations data on file, last reported at 2935000.0 in Q4 2025.
- Quarterly Cash from Operations rose 15.27% year-over-year to 2935000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 11716000.0 (up 16.87% YoY) and the FY2025 annual result came in at 9419000.0, up 33.17% from the prior year.
- Cash from Operations declined to 2935000.0 in Q4 2025, from 2877000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 11118000.0 in Q1 2021 to a low of 13698000.0 in Q4 2022.
- A 5-year average of 2455631.58 and a median of 3212000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2021 — Cash from Operations surged 330.1% — and 2022, when it slumped 466.03%.
- Tracing CLGN's Cash from Operations over 5 years: stood at 2420000.0 in 2021, then tumbled by 466.03% to 13698000.0 in 2022, then soared by 82.88% to 2345000.0 in 2023, then slumped by 47.72% to 3464000.0 in 2024, then advanced by 15.27% to 2935000.0 in 2025.
- The last three Cash from Operations figures came in at 2935000.0 (Q4 2025), 2877000.0 (Q3 2025), and 2440000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.94 Mn |
| Dec 31, 2025 | -2.94 Mn |
| Sep 30, 2025 | -2.88 Mn |
| Sep 30, 2025 | -2.88 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Dec 31, 2024 | -3.46 Mn |
| Dec 31, 2024 | -3.46 Mn |
| Sep 30, 2024 | -3.45 Mn |
| Sep 30, 2024 | -3.45 Mn |
| Jun 30, 2024 | -3.93 Mn |
| Jun 30, 2024 | -3.93 Mn |
| Mar 31, 2024 | -3.25 Mn |
| Mar 31, 2024 | -3.25 Mn |
| Dec 31, 2023 | -2.35 Mn |
| Dec 31, 2023 | -2.35 Mn |
| Sep 30, 2023 | 6.78 Mn |
| Sep 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | -3.74 Mn |
| Jun 30, 2023 | -3.74 Mn |